

Innovation

For Good Health





张方



2016

GB36000	“	”	Global Reporting Initiative,	” GRI ”
	G4	G4		

IFC

2016 1 1 2016 12 31

2016

2016

2016

A

<http://www.fosnpharma.com/news/le.html>

FSC

2016

.fos npharma.com



04

14



42



90



112

115

116

121

06

32



56



102




122

GB36002

131

G4

139 SGS



J I



A g st

September

12

Int iti eS rgical

Gland Pharma




7
Gland Pharma 86%
Gland Pharma FDA

8
“ “ “


9
S rgical
1

S rgical
Int iti e



December

6	2016		9		
	10				
		HLX07			
		HER2			12 10
		III			
		PA-824			







Care For Life



Continuous Innovation



Pursuit of Excellence



Win-Win Cooperation




1994 1998 8 2012 10
600196-SH 02196-


HK

44


45














11		•
12		• • • • • •

24

2016

	2016	Ambr Ambr Ambr Ambr Ambr Ambr
	2016	Gland Pharma
	2016 12	Intuitive Surgical
	2016	2015

/ 22 2016 VC /

2016 EHS

1

2

11 1 4 2016 12 31

3

4

A

5

/

2016



-
-
-
-

/

SAP

2017

SAP

2016

OA



-
-
-
-

88%



-



- 2016
-

2016

0A

42

23

2016

“ “ + ” ” ” ”

2016

IT

ISO27000

12



“ — — — ” IT
OpenStack
2016
“ OpenStack ”
OpenStack “ 2016
“ OpenStack ”



“ ” ,



“ ” ,

14.47%



99.72%

“ ” 2015 2016
14.47%

2016

EHS

2016 CSR




- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16

- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24

- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32



2016 CSR “ ”

GE

2016 6 WTO “

2030 ”


5 10 “

”

8 3 “

CSR

EHS




CSR

“ ”

CSR

CSR





					e	
2016	32	12	5	A	H	
1						32
2016			10			
	/					
7 22						
" 2016		"				
2000						
	"	"	"	"		
2016			92			
2016		300				
24						

2016

2016

7

2016

9

11

10

“ 2016

12

WTO

2016

9

"

2016

35

35

2016

90

2016

“ ”

Inc. 2016 Int iti e S rgical,

Pharma 2016 250,471 Gland
Int iti e S rgical

100 “ 2016 ” “ 2016
30
— “ 2016
” 20 30
20

“ ”

“ ”

“ ”

;

2016

500



500

2016

2016

12

“

”

APP

2016



181

49

99.86%

2016

CSR

2015

200

2016






GE

CSR

CSR

95%







2016

“

”

2016

1,025,954

1,462,882

2015

14.83%

2015

16.02%

357,155

280,584

209,278

2015

5.92%

14.05%


26.36

“

”


SOP

GCP



2012 -2016

单位：百万元





复星医药集团 2016 年研发投入 11.06 亿元（含资本化研发投入），同比增长超过 33.23%。



2016

11.06
33.23%



2016

1,025,954
14.83%

注：*1：2015 年数据按 2016 年口径重述，即 2015 年数据中包含新增核心产品注射用腺苷钴胺（米乐卡）的销售收入。
*2：同口径增减（%）为剔除 2015 年摩罗丹销售收入后的比例。

16.82%

35.43%

2016

18

5



/

N/A

ARTESUNPLUS

ARTESUN

2

N/A

N/A

LHRH

2016 ,

3018

020

“ ” B

(CHDX)

2016

266,391

2015

18.17%

2016

Alma Lasers

78,621

2015

14.19%

Alma

Alma Lasers

2016 Alma

Lasers
Lasers

6

CE

2

FDA

2016

Sisram

2016

CML

66

"

2016
19,000

2015

2016
54%

66

39

Int iti 55.006 *%4>Tj1.021 0>TjAD3EDmi itih8

2016




2016
9.58%

21.96 2015

2016

21.96
9.58%

2012 -2016



2016	180,612	26,615	7,673	2,001	7,614	841	225,356
2015	164,832	22,936	6,345	1,519	4,962	3	200,597
2014	131,210	20,678	4,759	1,408	4,850	285	163,190

*注：其它费用指辞退福利等其它费用。



温州老年病医院

2016 6



ISO15189



“ ”



2015 4

2016 6

80%



9


9

“

”

—

—



2016

14

13

	2015	2016
/	77	58
	358	401

13
cGMP

13
GMP
FDA
1
2
5
WHO-PQ
FDA

2016

2016 “
” (\
)

2016

EHS

“ ”
— “ ”

11

“ ”
3,018

2016

2015

2016

2016

2016

2016

14

CAPA

cGMP

OOS

GMP

2016

401

2010


GMP

cGMP
2016

58



3,018



2016

13

14



100%

401


58


2016 ISO13485 CE

0	16
2	14
3	0
7	5
5	33
1	22
2	15
0	39
5	1
4	0
3	1
1	0
2	13
2	60
9	39
5	136
2	7
0	0
4	0
2	0
58	401


2016	2	FDA	EIR
2016	4	FDA	EIR
2016	5	FDA	
2016	3		
2016	3	WHO	OSD-I
2016	3		INJ-I INJ-II
2016	7 12-16	ISO13485	Ila CE IIb CE III CE
2016	8 24 8 26	TUV EN ISO9001 EN ISO13485	CE
2016	5 30 31	TUV Rheinland LGA Prod cts EN ISO 13485	EN I13485:2012/AC GmbH

注：本表格只收录欧美规范市场检查情况。





	5	5	100%
	2	2	100%
	0	0	-
	0	0	-



2016

“

”

6,550

2016

2016

2016

2016

“

” 300


24

2016

40,000

5,100

2,000



GMP

2016
/

23

2016

IT

8

2016

2016

557

447
2016

2016
110

557

447

2016

671


2015

110

, ; , ,


671

14



2016

η	L



“ ” “ ”

2016



WIFI

2015 400 2 6 2300



2
2015 2300
6 400

2016 12 30

“ ”

2016 A

2016

“ ”

“ ”

“

”

“

”

“

“ ” “ ”

2016
17 ,

92%

95.39% 2016 “ ” (\) “ ”





95.39%

97.8% 95% 95% 96.8% 92.32%

9 5 3 0 0



注：此处的医疗纠纷定义为由司法介入的医疗纠纷













700

700

56.31

56.31



EHS

93,431
5.75
EHS




2015
2016




↑ 30.72%

21
10
ISO14001/OHSAS18001

8 1



EHS



Environment, Health and Safety (EHS) Policy

FosunPharma is dedicated to become a globally recognized healthcare company. Under the philosophy of integrity and sustainability, FosunPharma publishes its EHS policy that pursues the common developments of enterprises, environment and societies.

Thus, FosunPharma commits to:



EHS



1. Comply with all applicable laws, regulations and standards related to Environment, Health and Safety (EHS) in both China and any other regions/states where our business is registered;

EHS



2. Implement the strategies for sustainable developments of both environment and society, by preventing contaminants and pollution, saving energies, protecting ecological civilization, and building environment-friendly communities.



3. Provide safe and healthy workplaces for employees and our business partners, by taking all kinds of efforts to minimize risks, to prevent and eliminate possible hazards and injuries.



4. Care for the well-being of employees, by taking all means of reducing their exposures to occupational risks and hazards.



5. Conduct all necessary training courses, and ensure the completion of trainings and abidance to relevant safety rules that are mandatory for employment. Motivate employees to participate in EHS activities to increase EHS awareness.

EHS
EHS

EHS



6. Construct and enforce EHS management system throughout all business operations, to continuously improve our EHS performance.

EHS

EHS

FosunPharma is, and will continue to be, enforcing the implementation and proper execution of EHS policy in every business unit. Thank you all for our great supports.

EHS

EHS

2016

EHS

/



2016

290

650

.

2016



2016 6



21

19

2016

700

530

2.86

46.1



2016 / 8,769,376

2016 563,081 6.42% „Císařka“ 6.42% 6.42%



2016

	700
RO	31,800
	1,300
	2,500
	30,000
	450
	29,000
	396,000
	3,552
EDI	11,550
	6,000
	960
	32,984
	300
	120
	100
	7,415
	30

2016


			248.01	248.86	-	-
			354.62	352.28	-	-
1.			2,790	2,858.24	-	-
			984	959.90	-	-
			2,300	2,410.86	-	-
			1,225	1,329.22	-	-
2.			300	287.23	-	-
			12,500	12,635.03	-	-
			11,250	10,040.56	-	-
		10ml 2ml (	3,609.42	3,561.8	-	-
3.		10ml 2ml	3,568.77	3,531.59	-	-
		PVC190	27,540	29,659.91	-	-
		30ml	105.84	117.22	-	-
			2,068	2,031	-	-
1.			2,640	2,640	-	-
			480	470	-	-
			419	406	-	-
2.			250,100	253,790	-	-
			49,300	49,120	-	-
			400	247	-	-
3.			1.8	2.0	-	-
			2,000	985	-	-
			1,000	803	-	-
1.			8,770	8,770	-	-
			25,670	25,670	-	-
2.			36,600	36,600	-	-
			28,920	28,920	-	-
		L	300	290	-	-
1.		L	4,060	3,672	-	-
		DMEM/F12 L	425,850	379,500	-	-
2.		C4	27	28	-	-
			1,550	1,278	-	-
3.			1,107.15	1,248.71	-	-
			1,157	1,218	-	-
			1,180.7	1,007.46	-	-
			41,906	33,301	-	-
1.			26,430	30,899	-	-
			32,710	32,676	-	-
			14,700	12,232	-	-
2.			29,492	28,621	-	-
			668	675	-	-
			66,240	66,664	-	-
			11,203	9,858	-	-
3.			6.03	5.79	-	-
			1,322	1,146	-	-
			1,096	1,088	-	-

1.			8,000	6,000	-	-
			1,030	859	-	-
2.			1,030	859	-	-
			25.4	25.4	25.4	100%
			416	247	-	-
3.			2,000	660	-	-
			0	247	247	100%
			1,000	500	-	-
			98,500	86,600	-	-
1.			70,000	62,000	-	-
			42,720	42,720	-	-
			67,520	67,520	45000	66.6%
			2,000	1,529	-	-
			20,300	17,490	-	-
2.			16,375	1,1687	-	-
			2,030	1,450.5	-	-
			3,503	3,703	-	-
3.			1.43	1.42	0.14	9.6%
			18.46	15.87	0.3	1.9%
			358.5	358.5	-	-
1.	VP SFMAGT	L	32,500	9,100	-	-
	M199	L	3,400	1,300	-	-
2.			1,500	1,233	-	-
			1,600	1,168.2	-	-
			101.4	63.44	-	-
3.			116.1	162	-	-
			38.8	40.8	-	-
			47,500	38,611	-	-
1.			48,000	29,888	-	-
			25,900	30,290	-	-
			3,500	3,023	-	-
2.			2,000	1,938	-	-
	0		15,000	13,114	-	-
			4,100	3,850	-	-
			3,242	3,086	-	-
3.			9,150	7,618	-	-
			75	72	-	-
			2,360	2,595	-	-
1.			6.54	6.45	-	-
			24.15	24.20	-	-
			18.01	18.06	-	-
2.			2.14	2.13	-	-
			0.21	0.26	-	-
			620.55	845.16	-	-
3.			128.06	126.81	-	-
			21.58	28.26	-	-
			10.26	9.59	-	-
			56,709	56,300	-	-
1.			11,894	13,154	-	-
			11,400	11,710	-	-
			6,675	7,507	-	-

			74,977	74,048	-	-
2.			62,940	62,310	-	-
			20,373	20,784	-	-
3.		PVC	90,660	91,168	-	-
			2,006	2,056	-	-
1.		L	2,968,294	3,139,334	-	-
			24.54	29.96	-	-
2.			2,452	2,455	2062	84.0%
		L	670	889	-	-
			9,783	9,329	-	-
3.			3,896	3,563	-	-
			3,319	3,521	-	-
			3,700	3,641	-	-
1.			88,470	75,230	-	-
			101,970	93,250	-	-
			125,700	104,970	-	-
2.			15,650	14,371	-	-
			15,600	11,911	-	-
			12,679	10,682	-	-
3.		PVC	43,888	46,661	-	-
			43,776	47,283	-	-
1.			141	136	-	-
			77.8	84.2	-	-
2.			3,000	3,830	-	-
			10,457	10,419	-	-
3.			23,640	22,830	-	-
			22,416	22,841	-	-
1.			226	210	-	-
		N-N-	244	223	-	-
			289	284	-	-
			1,639	1,560	-	-
2.			934	916	-	-
			577	542	-	-
			530	504	-	-
			3.2	2.88	-	-
1.			5,930	5,820	-	-
			4,300	4,300	-	-
2.			11,900	9,700	-	-
			15,937.4	15,887.6	-	-
3.			21,020.5	18,357.5	-	-
			19,240.9	17,238.9	-	-
1.			12,052	12,052	-	-
			10,916	10,916	-	-
			6,038	6,038	-	-
2.			9,760	10,168	408	4.0%
			566	1,783	1,217	68.3%
			230.10	174.26	-	-
3.			209.66	174.41	-	-
			1.34	1.50	0.16	10.7%
			69.63	55.56	14.07	25.3%

1.		474.94	474.75	-	-
		1,749	1,657	-	-
		38	41	-	-
2.		3,000	850	-	-
		22	22.9	-	-
		11.8	10.15	10.15	100%
1.				-	-
2.				-	-
3.				-	-
1.		15	15	-	-
		15	15	-	-
		165	165	-	-
2.		50	50	-	-
		105	105	-	-
		148	148	-	-
		6,500	6,500	-	-
3.	20ml)	1.247	1.247	-	-
		2.1	2.1	-	-
		0.56	0.56	-	-
		7.55	4.6	-	-
		12.96	8.8	-	-
1.		7.8	6.6	1	15.2%
		10.25	7.75	3	38.7%
		6.4	5.12	1.4	27.3%
		3.78	5.04	-	-
3.		903	870	-	-
	20	200	292	-	-
		1,200	1,150	-	-
1.	V	3,100	3,100	-	-
		1,000	890	-	-
		2,000	1,980	-	-
3.		10	10	-	-
		5	5	-	-
	5.5# 7.0#	12	11	-	-
2.	84	4	3.6	-	-
	10ml 20ml	17	17	-	-
		21.2	21.2	-	-
3.		3	3	-	-
	CT	3	3	-	-
2.		159.64	159.64	-	-
	40L	2,301	2,301	-	-
3.		11.4	9.5	-	-
	L	520	520	-	-
	25	138	138	-	-
2.	L	1,444	1,444	-	-
	40L 10L	316	316	-	-
		334.2	334.2	-	-
2.		1,000	1,000	-	-

.....



2016

Alma	3.	865	865	-	-
		10	5	-	-
		10	5	1	20.0%
	3.	6	1	-	-
		15	10	5	50.0%


注：表中除已注明单位外其他均以公斤计。

ÿ Ë Ë ÿ

ÿ ÿ

511 600m³/d
 + + +TRIC + A/O +

COD BOD SS 2016



2016

91

2016
 VOCs

VOCs

2016
 VOCs

VOCs

2016

91

0.000	0.001	0.000	0.12					
0.000	0.010	0.130	0.07					
3.359	0.611	0.370	0.00					
0.002	0.001	0.000	0.00					
32.863	23.886	8.817	0.00					
419.839	441.936	6.187	0.00				+	
0.000	15.747	1.030	0.00					
3.384	2.269	1.086	0.00					
0.869	0.000	0.185	0.00					35
0.000	0.000	0.000	1.34				+	20
4.007	0.180	0.604	0.00					
0.000	0.000	0.000	0.01					
0.03	0.038	0.013	-					
0.000	0.000	0.000	0.55	"	+		+	"
1.414	0.000	0.007	0.00		1.			2.
0.002	0.000	0.000	0.00					
0.010	0.014	0.014	0.00					



" " 2016



VOCs
30

200 WWTU

2016

172.94	121	13.44	38.5	0	37.3	0	1.2	
1,365	15	1,300	50	0	47.7	0	2.3	1300
86.48	22	36	28.48	0	28.48	0	0	
30.2	21.3	4.8	4.1	0	4.1	0	0	
76.79	48	25.32	3.47	0	0	0	3.47	
3.37	3	0.2	0.17	0	0.17	0	0	
1,825.34	80	1,653	92.34	0	46.05	46.29	0	1633
29.55	10	7	12.55	0	11.6	0	0.95	4j 1.504983>Tj28-
6193.53	1,522	4490.49	181.04	0	181.04	0	0	:>1, j 1.j /C2_1 j 1. 1.0
QQ#U0DHP38B3j(8)Tj1>Tj25j1.43j1.3886427AF>Tj1.0.Td27AF>Tj1.3804>Tj2FC>Tj1.019.0249D8C7C>T191.005.0.B7A8C7C>T191.005.03F4A8C7C>T191.005.03BB08C7C>T191.005.0.EA0Td								

229.67	146	0	83.67	0	83.67	0	0
738	535	0	203	0	203	0	0
23.87	11.91	11.91	0.04	0	0.04	0	0
192	75	0	117	0	0	0	117
0.67	0.63	0.02	0.02	0	0	0	0.02
15.3	9.6	0	5.7	0	2.5	0	3.3
25.3	12	12	1.3	0	1.3	0	0
3.37	2.08	1.08	0.21	0	0.21	0	0
0.84	0.75	0	0.09	0	0.09	0	0
1.51	1.5	0.01	0	0	0	0	0
63	60	3	0	0	0	0	0
13	13	0	0	0	0	0	0
0.5	0.5	0	0	0	0	0	0
15	5	10	0	0	0	0	0
78	50	28	0	0	0	0	0
0.08	0.08	0	0	0	0	0	0

9.30	35.20
519.20	28.50
45.00	42.00
0.35	29.36
/	22.90
22.90	17.75
5.00	1.00
UPS pH	20.00
20.00	100.00
1.00	13.49
206.00	156.00
218.00	83.00
1.21	7.14

2016

1,319

3,346

2,027

2016

§

2016

“ ”



2016 16

EHS

8 25

1 5 5

66

2016

2016 9 10
24 120

16
100%

600

66

600

“ ”

2016


CO₂ 75

2016


2

“ ”


0



2016



2016



										()	()	()
2014	15,757	0	0.006	0.46	-	-	14.88%	2,060				
2015	15,187	0.006	0.026	0.392	0.424	0.533	12.57%	4,505	71,474	4.71		
2016	16,235	0	0.044	0.072	0.116	0.21	14.89%	3,155	93,431	5.75		



20 20

779	1,607,070	0	0	1	0	1	0.12	0.00	1	3	0.12	0.37	0	105
169	344,110	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
306	708,990	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
157	375,303	0	0	0	1	1	0.53	0.00	1	2	0.53	1.07	0	40
210	443,520	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
98	250,880	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
943	1,968,984	0	0	1	1	2	0.20	0.00	0	0	0	0	0	0.00



API 605 DCS API




2016



100%

100% 2016 0 100% 2,417 2016 0 100% 2,417



2016

354	45.44%	354	100%	0
140	82.84%	140	100%	0
8	2.61%	8	100%	0

3,155

	21.52	41.90
	7.55	28.00
	101.00	0.00
	0.78	30.75
	18.80	20.28
	9.20	1.00
	262.00	/ 52.50
	6.00	8.10
	29.00	128.00
	261.40	91.00
	20.59	11.85
	0.88	0.94
/	7.00	14.70
	39.81	40.88
	37.57	159.10
	224.70	122.30
-	-	1.10
-	-	0.50
	2.50	1.50
	1.65	11.19
	18.00	3.40
	605.00	60.00
DCS		
-	-	2.52
	8.00	15.00
	1.62	3.90
	58.00	267.30
	4.00	0.50
	220.08	7.50
	3.85	1.20
	1.00	0.90
	3.00	15.00
-	-	0.40

Item	Unit	Price	Quantity	Total
1.00	1.00	9.50	1.10	-
13.00	0.70			

EHS


Year	2016	2015
2016	34,913	22.2%
2015	93,431	5.75

[illegible]

				%	h					h				
693	693	100%	1392			2,989	5,218.5	EHS		1,205	1,645.5		EHS	
260	260	100%	6392			402	603			227	303	PPE	EHS	
390	390	100%	1550			56	672			1,860	1,860	GB30871		
64	64	100%	571			795	1,745.25			911	1,956.25			
77	77	100%	1752			600	2,700	EHS		182	341			
129	129	100%	512			680	1,902.5	EHS		805	1428.5			
91	91	100%	3856			2,080	4,835	EHS		1125	2,838.5	LOTO		
16	16	100%	3931			330	419.5	EHS		122	126	HAZOP	JHA	
161	161	100%	1552			1,353	1,731	EHS		108	290	MG&LOTO		
-	-	-	-	-	-	96	138.88	EHS		71	98.5			
-	-	-	-	-	-	12	1	EHS		-	-		-	
-	-	-	-	-	-	650	300	EHS		60	360			
33	33	100%	792			465	697.5	EHS		465	697.5			
72	72	100%	1154			108	171	EHS		5	5.5			
136	136	100%	3,600			993	4,000	EHS		215	1,700			
4	4	100%	3			-	-	-		26	16			
42	42	100%	1008			50	50			63	63			
2	2	100%	64			124	114	EHS		166	138		loto	
56	56	100%	224			3,006	2,750			630	1,863			
50	48	100%	48			100	95	EHS		50	45			
9	9	100%	48			19	38	EHS		19	152			
856	507	100%	277			-	-	-		18	41.5			
15	15	100%	180			1,462	3,100	EHS		22	55			
2	2	100%	40			151	377	EHS		2	5			
12	12	100%	6			-	-	-		-	-		-	
2	2	100%	48			258	169	EHS		152	268			
4	4	100%	48			577	577	EHS		2	24			
-	-	-	-	-	-	1	8	EHS		-	-		-	
-	-	-	-	-	-	4	8	EHS		-	-		-	

50.96%

49.04%



	2016	12	31		19,523	2015
9.4%						
	2016		40		65.6%	
	2016					134
27.6 %			14.85 %			
59.0 %			(QA QC)		2,194	
14.2%						
			2016			
31.0 %						

单位：人

2016	19,523	9,574	9,949
2015	17,842	8,653	9,189
2014	18,081	8,800	9,281
2013	16,791	8,246	8,545
2012	14,357	7,222	7,135

单位：人

2016	134	1021	5,395	4,977	7,996
2015	105	889	4,453	4,643	7,752
2014	93	749	4,229	4,693	8,317
2013	80	637	3,794	4,368	7,912
2012	50	472	2,931	3,364	7,540

单位：人

66

99

2016

2016

2016



2016

11 12

11 12


11 12

/

11



	2012	2013	2014	2015	2016
	813	931	879	557	819
/	-	-	36	28	33
/	-	-	37	29	31
/	-	-	34	30	37
	118	154	180	226	249
	4,610	5,844	20,815	6,627	6,348
	8,971	14,050	18,278	20,697	21,255
	405,406	543,758	652,405	577,366	710,701
	317	434	714	924	543
	23,392	44,080	44,681	53,994	65,639



: 2016



QA CGMP QBD FDA

GMP GDP

:

2016 11

1 120



: (CML)

(CML)

360

“

”

2016

Pre-IPO

2007

2016

50.96%

0.36%



2.49%

100%

100%
100%

“

”



单位：人

2012	2013	2014	2015	2016
40	49	52	64	47
2	7	3	5	3
4	9	5	4	11
160	159	193	233	283
23	37	32	54	101
33	30	21	46	64

2012	2013	2014	2015	2016
20.60%	19.12%	11.48%	18.45%	23.92%

注：晋升 / 期初期末平均数

2012	2013	2014	2015	2016
18.90%	17.57%	17.05%	17.12%	17.89%
17.21%	14.76%	14.50%	13.24%	14.86%

注：流出率 = 所有离职职工数 *2/（期初 + 期末总人数）；流失率 = 主动离职职工人数 *2/（期初 + 期末总人数）

2016

“ ”

EAP

2016 10

63









>300

>90

1

2016

2016 2.99 *

2008 5 14

2016

OA

2016

“

”

2016

23

2016

ISO19600

2016

797

1998

“

”




2016

500

“

2016

500



“ ”

2016

645

100

“ ”

2016

15

29

4

10

15

60

500

100

9 “ ”

“ ”

30

3

5

207

2016 10

17

2016 “ ”

“ ”

6

2016

15



9 9

fos nfo ndation

“

”

3 22

/

“

”

“

”

“

”

2016

2020

1000

1000

4 27

2016

2

“

”

22

6.6

4

6

“

”

2016 4

“

”

12 50

“

”

30

•

“

”

“

”

2016

, 2016

“

”

“

”

○

100 2010

5

2010 7 7

25

30 17000

10 1100

3-5

2016

2016 10 207

90

2-3 2016 5000

65 65

21



90

>90







	2012 ()	2013 ()	2014	2015	2016
*	6.05	6.84	7.21	7.86	9.19
	0.80	0.90	0.92	1.07	1.21
	0.44	0.46	0.58	0.72	0.91
	8.24%	6.22%	8.43%	9.57%	10.63%

* 注：归属于上市公司股东的每股净资产（元/股）= 归属于母公司股东权益合计 / 期末股数

	2012 ()	2013 ()	2014	2015	2016
	734,078	999,641	1,202,553	1,260,865	1,462,882
	186,598	214,062	192,501	234,662	212,540
	203,599	281,883	239,435	329,717	339,942
	9,725	10,436	34,047	10,666	19,511
	1,020	1,692	1,676	3,200	2,298
	282	1,045	85	362	974
	212,304	290,627	271,805	337,183	357,155
	28,376	50,632	34,821	50,117	35,021
	183,927	239,995	236,984	287,066	322,134
	156,392	202,706	211,287	246,009	280,584
	27,536	37,289	25,697	41,057	41,550
	78,900	105,080	126,821	143,449	163,136
	333	424	735	847	797

注：本公司在编制 2015 年度财务报表时，已全面执行财政部于 2014 年 1 月至 7 月期间颁布的 9 项企业会计准则，因会计政策变更，本公司在上述列表中追溯并调整了绩效指标和社会指标。

2012	2013	2014	2015	2016
	1.90	2.36	2.76	2.99
	()			
14,357	16,791	18,081	17,842	19,523
7,222	8,246	8,800	8,653	9,574
7,135	8,545	9,281	9,189	9,949
522	717	842	994	1,155
100%	100%	100%	100%	100%
76,594	124,594	163,190	200,435	219,600
()	()			
100%	100%	100%	100%	100%
0.52%	0.38%	0.41%	0.36%	0.36%
2.80	2.39%	2.30%	2.20%	2.48
400	386	416	393	487
410,016	549,602	673,220	583,992	717,049
		()		
20.60%	19.12%	11.48%	18.45%	23.92%
18.90%	17.57%	17.05%	17.12%	17.89%
	100%	100%	100%	100%

2012	2013	2014	2015	2016
107	119	125	161	173
3	8	11	13	30
3.70	5.05	6.85	8.30	11.06
70	72	86	89	103
33	32	36	15	30
766	779	856	887	995

86 21 33987125

1289 A

200233

s nl@fos npharma.com

.fos npharma.com

2016

- 1
- 2
- 3
- 4
- 5

2016

上海市经济团体联合会执行副会长兼秘书长 李鹤富

责扬天下（北京）管理顾问有限公司总经理 陈伟征

2016

2016

2016

“ ”

润灵环球（RKS）创始人 张浩而

争

Alma Lasers

[illegible]

HECC

Electro deion i ation

RO

$$\text{CO}_2$$
$$\text{CH}_4$$
$$\text{N}_2\text{O}$$

Personal Protection Equipment

Lock O_t & Tag O_t

99

22

Process Safety Management

High Risk Operation

Establishment Inspection Report

A handwritten signature in black ink, consisting of stylized, overlapping loops and strokes.



GB/T36002

L-1

L-1-1	98-99
L-1-2	92-99
L-1-3	92-99
L-1-4	98-99
L-1-5	98-99
L-1-6	98-99
L-1-7	22 98-99
L-1-8	98-99
L-1-9	50-51

L-2

L-2-1	58-60 80-84
L-2-2	80-84 100
L-2-3	98
L-2-4	98-100
L-2-5	38-39
L-2-6	38-39 98-99
L-2-7	98-99
L-2-8	92-100
L-2-9	92-100
L-2-10	98-100
L-2-11	98-99

L-3

L-3-1	99
L-3-2	99 104-105
L-3-3	98-99 104-105
L-3-4	98-99 104-105
L-3-5	21-22 104-105

L-4

GB/T36002

L-4-1	58
L-4-2	80-81
L-4-3	80
L-4-4	81
L-4-5	83-84
L-4-6	81-82
L-4-7	81
L-4-8	81
L-4-9	81
L-4-10	86-88
L-4-11	89
L-5	
L-5-1	93-97
L-5-2	98-99
L-5-3	98-99
H-1	
H-1-1	58-59
H-1-2	71-74
H-1-3	71-74
H-1-4	71-74
H-1-5	71-74
H-1-6	71-74
H-1-7	75-76
H-1-8	75-76
H-1-9	60
H-2	
H-2-1	60-63
H-2-2	60-63
H-2-3	64-65
H-2-4	64

GB/T36002

H-2-5		65
H-2-6		64-65 72-73
H-2-7		78
H-2-8		58-61
H-2-9		57-89
H-3		
H-3-1		79-80
H-3-2		79-80
H-3-3		79-80
H-3-4		60-65
H-3-5	GHG	79
H-3-6		64-65
H-3-7		79-80
H-3-8		60-61
H-3-9		79
H-3-10		
H-4		
H-4-1		79
H-4-2		79
H-4-3		79
H-4-4		65 79
H-4-5		79
H-4-6	“ ”	61-77
H-4-7		
H-4-8		
H-4-9		78
H-4-10		79

GB/T36002

H-4-11	79
G-1	
G-1-1	104-105
G-1-2	105
G-1-3	105
G-1-4	104-105
G-1-5	19
G-1-6	104-105
G-1-7	104-105
G-1-8	
G-1-9	104-105
G-1-10	104-105
G-2	
G-2-1	48
G-2-2	
G-2-3	48
G-2-4	
G-2-5	98-99
G-3	
G-3-1	50
G-3-2	50
G-3-3	28
G-3-4	
G-3-5	
G-3-6	50
G-4	
G-4-1	34
G-4-2	38


GB/T36002

G-4-3	34
G-4-4	38
G-4-5	38
X-1	
X-1-1	48
X-1-2	48
X-1-3	48
X-1-4	46 48
X-1-5	48
X-1-6	
X-1-7	48
X-1-8	48
X-1-9	48
X-2	
X-2-1	44-48
X-2-2	80-84
X-2-3	47
X-2-4	48
X-2-5	48
X-2-6	34
X-2-7	46
X-2-8	44-46
X-2-9	46-47
X-2-10	49
X-3	
X-3-1	48

GB/T36002

X-3-2

44-46



X-4-1

47

X-4-2

47

X-4-3

X-4-4

48

X-4-5

27 48

X-4-6

27 48

X-4-7

27 47-48

X-5

X-5-1

47-48

X-5-2

47-48

X-5-3

47-48

X-5-4

47-48

X-5-5

47-48

X-5-6

47-48

X-5-7

22

X-5-8

22

X-5-9

22

X-6

X-6-1

48

X-6-2

98

X-6-3

47

X-6-4

48

X-6-5

GB/T36002

X-6-6	47	53
X-7		
X-7-1	86-88	
X-7-2	48	
X-7-3	48	
X-7-4	27	
X-7-5	27	
X-7-6		
X-7-7		
X-7-8		
X-7-9	27	
X-7-10		
S-1		
S-1-1	108	
S-1-2		
S-1-3	105	107
S-1-4	104-105	
S-1-5	108	
S-1-6	108	
S-2		
S-2-1	106	
S-2-2	106	
S-2-3	107	
S-2-4		
S-2-5		
S-3		
S-3-1	92	
S-3-2	93-94	
S-3-3	50	
S-3-4	92	

GB/T36002

[illegible]

G4

G4									
)W0m)50m)4Mm&(									
G4-1*									3
G4-2		&)						3	4 16-17 139
G4-3*									10-11
G4-4*		)W0P							12 44
G4-5*									
G4-6*		)m)W0h)50h)W0h)							12 18
G4-7*								4	11 19
G4-8*		&(						18	35-37 42 44
G4-9*									12
G4-10*	a. . 1W0m)								
UNGC	b. .								

G4

[illegible]

G4

G4-41					19
G4-42				17 44 58	104
G4-43				34-39 56-91	104
G4-44	a.				
	b.				19-22
G4-45	a.				
	b.			3 19	27-30
G4-46					19-22
G4-47				21 35-38	104
G4-48					19
G4-49					19
G4-50					19
G4-51	a.				
	b.			38-39 59	98
G4-52					19
G4-53					
G4-54					
G4-55					

G4-56*				11 21
G4-57				105-106
G4-58				104-105

G4

G4-EC1				38-39 98	112-113
--------	--	--	--	----------	---------

G4

G4-EC2	58-59
G4-EC3	39 98
G4-EC4	
G4-EC5	39 90
G4-EC6	92-93
G4-EC7	105-107
G4-EC8	34-35
G4-EC9	46-48

G4-EN1	50
G4-EN2	60-71
G4-EN3	65-74
G4-EN4	
G4-EN5	61
G4-EN6	64-65
G4-EN7	64
G4-EN8	61
G4-EN9	
G4-EN10	65

G4-EN11

G4-EN12

G4-EN13

G4-EN14

(IUCN)

G4

G4-EN15		79
G4-EN16		79
G4-EN17		62 79
G4-EN18		
G4-EN19		
G4-EN20	(ODS)	
G4-EN21		71
G4-EN22		72
G4-EN23		75-76
G4-EN24		
G4-EN25	I II III VIII	
G4-EN26		
G4-EN27		60
G4-EN28		66-70
G4-EN29		
G4-EN30		63
G4-EN31		77
G4-EN32		78
G4-EN33		78
G4-EN34		

G4

G4-LA1		93	99
G4-LA2		38-39	98
G4-LA3	/		98
G4-LA4			98
G4-LA5		83-84	
G4-LA6		80-83	
G4-LA7		83-84	
G4-LA8		86-88	
G4-LA9		95	
G4-LA10		93-97	
G4-LA11		98	
G4-LA12		93	
G4-LA13		38-39	98
G4-LA14			
G4-LA15			
G4-LA16			98

G4-HR1			
G4-HR2			93-97

G4-HR

G4



G4-SO7

G4-SO8

G4-SO9

G4-SO10 50 78

G4-SO11

G4-PR1

G4-PR2

G4-PR3 44-46 48

G4-PR4

G4-PR5 27 31 53

G4-PR6

G4-PR7

G4-PR8

G4-PR9



4

“

”

12

50

“

”

30

—

—

验证报告—上海复星医药（集团）股份有限公司

1) 股份有限公司（以下简称“复星医药”）

SGS 验证了复星医药 2016 年度企业社会责任报告中的数据。并对位于上海市宜山路 1289 号的上海复星医药（集团）股份有限公司的管理体系进行了验证。

其总裁以及管理层负责，SGS 并未参与。

本报告中的意见，由本验证师负责复星医药的。

1) 包括全球报告倡议组织（GRI）可持续发展报告中的验证水平。

指南（2013）》评估报告。

导与员工，以及对相关文件和记录进行核实。

证。

提供的服务包括管理系统和服务认证；质量、环境、报告验证。SGS 申明与复星医药互为完全独立的组织和利益冲突。

通标标准技术服务股份有限公司上海分公司可持续发展医药（集团）股份有限公司 2016 年度企业社会责任

验证的性质和范围

通标标准技术服务股份有限公司上海分公司（SGS）经上海复星医药（集团）

验证范围包括本报告所含文本以及附随

复星医药的 2016 年度企业社会责任报告中的信息和介绍

2016 年度企业社会责任报告任何材料的准备。

我们的责任是在规定的认证范围内表达我们的意见，数据，利益相关方。

《SGS 可持续发展报告验证程序》基于国际认可的导则报告指南的准确性和可靠性准则，以及 AA1000 系列标准。

本报告以中级审查进行验证，所用规章用于：

- 评估内容真实性；以及
- 根据《全球报告倡议组织可持续发展报告

验证过程包括验证前调研、现场验审、访谈相关领


本次验证未包含对独立审计的财务信息的溯源及验

独立性与能力声明

SGS 是全球领先的检验、鉴定、测试和认证机构。社会和道德审计及培训；环境、社会 and 可持续发展组织。对该组织及其附属机构和利益相关方不存在偏

可持续发展背景

复星医药从经济、环境与社会方面展现其为实现可持续发展所做出的努力，并将这些绩效结合可持续发展的背景呈现。



14 19 14 19 14 19 14 19 14 19 14 19 14 19

-
-
-
-
-
-
-



()

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

: 1289 A
(86 21) 3398 7000
(86 21) 3398 7020
.fosunpharma.com
200233

-
- Designed by Brand & Public Relations Department of Fosun Pharmaceutical (Group) Co., Ltd.